

# Masaaki Motoori

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6476954/publications.pdf>

Version: 2024-02-01

41  
papers

1,022  
citations

430442

18  
h-index

454577

30  
g-index

45  
all docs

45  
docs citations

45  
times ranked

1100  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2022, 126, 1555-1562.	2.9	13
2	Comparison of synbiotics combined with enteral nutrition and prophylactic antibiotics as supportive care in patients with esophageal cancer undergoing neoadjuvant chemotherapy: A multicenter randomized study. <i>Clinical Nutrition</i> , 2022, 41, 1112-1121.	2.3	8
3	Risk Factors for Para-Aortic Lymph Node Metastasis in Esophagogastric Junction Cancer: Results from a Prospective Nationwide Multicenter Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 5649-5654.	0.7	3
4	The Impact of Perioperative Fluid Balance on Postoperative Complications after Esophagectomy for Esophageal Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 3219.	1.0	4
5	Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OCSG1003). <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 75-82.	1.2	16
6	Predictive value of preoperative echocardiographic assessment for postoperative atrial fibrillation after esophagectomy for esophageal cancer. <i>Esophagus</i> , 2021, 18, 496-503.	1.0	8
7	Two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for treating locally advanced esophageal cancer: short-term outcomes of a multicenter randomized phase II trial. <i>Esophagus</i> , 2021, 18, 825-834.	1.0	14
8	Postoperative pneumonia in the acute phase is an important prognostic factor in patients with esophageal cancer. <i>Surgery</i> , 2021, 170, 469-477.	1.0	13
9	Influences of the Charlson Comorbidity Index and Nutrition Status on Prognosis After Esophageal Cancer Surgery. <i>Annals of Surgical Oncology</i> , 2021, 28, 7173-7182.	0.7	24
10	Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer. <i>Clinical Nutrition</i> , 2021, 40, 4380-4385.	2.3	18
11	Successful treatment of remnant gastric cancer with afferent loop syndrome managed by percutaneous transhepatic cholangial drainage followed by elective gastrectomy: a case report. <i>Surgical Case Reports</i> , 2021, 7, 219.	0.2	2
12	Are Incidental Minute Pulmonary Nodules Ultimately Determined to Be Metastatic Nodules in Esophageal Cancer Patients?. <i>Oncology</i> , 2021, 99, 547-554.	0.9	0
13	Multicenter Randomized Phase 2 Trial Comparing Chemoradiotherapy and Docetaxel Plus 5-Fluorouracil and Cisplatin Chemotherapy as Initial Induction Therapy for Subsequent Conversion Surgery in Patients With Clinical T4b Esophageal Cancer. <i>Annals of Surgery</i> , 2021, 274, e465-e472.	2.1	27
14	Correlation between Skeletal Muscle Mass and Adverse Events of Neoadjuvant Chemotherapy in Patients with Gastric Cancer. <i>Oncology</i> , 2020, 98, 29-34.	0.9	10
15	The Pattern of Residual Tumor After Neoadjuvant Chemotherapy for Locally Advanced Esophageal Cancer and Its Clinical Significance. <i>Annals of Surgery</i> , 2020, 271, 875-884.	2.1	39
16	Impact of preoperative fecal short chain fatty acids on postoperative infectious complications in esophageal cancer patients. <i>BMC Gastroenterology</i> , 2020, 20, 74.	0.8	7
17	Prognostic Impact of Postoperative Complications following Salvage Esophagectomy for Esophageal Cancer after Definitive Chemoradiotherapy. <i>Oncology</i> , 2020, 98, 280-288.	0.9	13
18	Metabolic Tumor Volume Change Predicts Long-term Survival and Histological Response to Preoperative Chemotherapy in Locally Advanced Esophageal Cancer. <i>Annals of Surgery</i> , 2019, 270, 1090-1095.	2.1	47

#	ARTICLE	IF	CITATIONS
19	Clinical Implications of Conversion Surgery After Induction Therapy for T4b Thoracic Esophageal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 4737-4743.	0.7	25
20	Impact of Age on Long-Term Survival in Patients with Esophageal Cancer Who Underwent Transthoracic Esophagectomy. <i>Oncology</i> , 2019, 97, 149-154.	0.9	9
21	Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 4754-4764.	0.7	21
22	Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery. <i>Oncology</i> , 2019, 97, 348-355.	0.9	20
23	The Significance of SCC and CEA mRNA in the Pleural Cavity After Lymphadenectomy in Esophageal Cancer Patients who Underwent Preoperative Treatment. <i>World Journal of Surgery</i> , 2018, 42, 749-757.	0.8	9
24	Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer. <i>Oncology</i> , 2018, 95, 281-287.	0.9	32
25	Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients. <i>Clinical Nutrition</i> , 2017, 36, 93-99.	2.3	78
26	Clinical Assessment of Reconstruction Involving Gastric Pull-up Combined with Free Jejunal Graft After Total Pharyngolaryngoesophagectomy. <i>World Journal of Surgery</i> , 2017, 41, 2329-2336.	0.8	8
27	Feasibility of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil versus Adriamycin, Cisplatin, and 5-Fluorouracil for Resectable Advanced Esophageal Cancer. <i>Oncology</i> , 2017, 92, 101-108.	0.9	34
28	Randomized study of the clinical effects of ω-3 fatty acid-containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. <i>Nutrition</i> , 2017, 33, 204-210.	1.1	43
29	Usefulness of diagnostic laparoscopy with 5-aminolevulinic acid (ALA)-mediated photodynamic diagnosis for the detection of peritoneal micrometastasis in advanced gastric cancer after chemotherapy. <i>Surgery Today</i> , 2016, 46, 1427-1434.	0.7	22
30	Clinical importance of a transcription reverse-transcription concerted (TRC) diagnosis using peritoneal lavage fluids obtained pre- and post-lymphadenectomy from gastric cancer patients. <i>Surgery Today</i> , 2016, 46, 654-660.	0.7	13
31	Closure method for thick pancreas stump after distal pancreatectomy: soft coagulation and polyglycolic acid felt with fibrin glue. <i>Langenbeck's Archives of Surgery</i> , 2015, 400, 843-848.	0.8	19
32	Relationship between Immunological Parameters and the Severity of Neutropenia and Effect of Enteral Nutrition on Immune Status during Neoadjuvant Chemotherapy on Patients with Advanced Esophageal Cancer. <i>Oncology</i> , 2012, 83, 91-100.	0.9	19
33	Impact of perioperative administration of synbiotics in patients with esophageal cancer undergoing esophagectomy: A prospective randomized controlled trial. <i>Surgery</i> , 2012, 152, 832-842.	1.0	71
34	Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. <i>Clinical Nutrition</i> , 2012, 31, 330-336.	2.3	80
35	Comparison Between Radical Esophagectomy and Definitive Chemoradiotherapy in Patients with Clinical T1bN0M0 Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 2135-2141.	0.7	75
36	Chemotherapy-induced toxicities and treatment efficacy in advanced esophageal cancer treated with neoadjuvant chemotherapy followed by surgery. <i>Esophagus</i> , 2011, 8, 81-87.	1.0	11

#	ARTICLE	IF	CITATIONS
37	Multicenter Phase I/II Study of Docetaxel, Cisplatin and Fluorouracil Combination Chemotherapy in Patients with Advanced or Recurrent Squamous Cell Carcinoma of the Esophagus. <i>Oncology</i> , 2011, 80, 307-313.	0.9	95
38	Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples. <i>International Journal of Oncology</i> , 2010, 37, 1113-20.	1.4	21
39	CEA-Antigen and SCC-Antigen mRNA Expression in Peripheral Blood Predict Hematogenous Recurrence After Resection in Patients with Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 2779-2786.	0.7	37
40	The feasibility of using biopsy samples from esophageal cancer for comprehensive gene expression profiling. <i>International Journal of Oncology</i> , 2009, 35, 265-71.	1.4	1
41	Prediction of peritoneal metastasis in advanced gastric cancer by gene expression profiling of the primary site. <i>European Journal of Cancer</i> , 2006, 42, 1897-1903.	1.3	13